Transparency Document
NCCN Guidelines for Castleman Disease V.1.2025
| Request Number | Guideline Page | Specific change request | Panel Decision | Comment | Institution Vote |
|---|---|---|---|---|---|
| 4766 - Internal Request | CD-C 1 of 3 |
First-line therapy MCD - Criteria for active disease present but no organ failure HHV8-negative/HIV-1-negative (iMCD -Nonsevere) • Add: RCVP (rituximab, cyclophosphamide, vincristine, prednisone) MCD - Fulminant/severe ± organ failure Fulminant/severe HHV8-negative (iMCD) • Add the following: • CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) ± rituximab • CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone) ± rituximab • CVP (cyclophosphamide, vincristine, prednisone) ± rituximab • Siltuximab • If not a candidate for combination therapy: Rituximab Fulminant/severe HHV8-positive MCD • Add the following: • Rituximab + liposomal doxorubicin • Rituximab + prednisone + liposomal doxorubicin |
Change made |
Yes: 33 No: 0 Abstain:0 Absent:1 |
|
| 4767 - Internal Request | CD-C 2 of 3 |
Second-Line and Subsequent Therapy for Relapsed/Refractory or Progressive Disease HHV8(+) - Criteria for active disease present with no organ failure or Fulminant/Severe disease [HHV8(+) or HHV8(-)] with no organ failure Preferred regimens • Add: Siltuximab (if HHV8-negative) Other recommended regimens • Add: Sirolimus Fulminant/Severe disease [HHV8(+) or HHV8(-)] with organ failure Preferred regimens • Add: Siltuximab (if HHV8-negative) |
Change made |
Yes: 33 No: 0 Abstain:0 Absent:1 |